Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome

CompletedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

July 21, 2023

Study Completion Date

July 21, 2023

Conditions
Angelman SyndromePrader-Willi Syndrome
Interventions
DIAGNOSTIC_TEST

Newborn Screening Assay

"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."

Trial Locations (1)

53705

University of Wisconsin School of Medicine and Public Health, Madison

All Listed Sponsors
collaborator

Ultragenyx Pharmaceutical Inc

INDUSTRY

lead

University of Wisconsin, Madison

OTHER